Sarepta surges on expanded approval of muscular dystrophy drug
In this article:
Shares of Sarepta (SRPT) are surging after receiving expanded approval from the Food and Drug Administration for its muscular dystrophy drug, Elevidys.
Yahoo Finance's Anjalee Khemlani reports more on the approval and what it means for patients seeking treatment.
For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.
This post was written by Melanie Riehl